JAPAN-CORN-STARCH
Japan Corn Starch Co., Ltd. (Minato-ku, Tokyo; Soichiro Kurachi, president. Hereby, “Japan Corn Starch” or “the company”), the largest corn wet miller in Japan has been pursuing excellent flavor in the increasingly diverse food industry, and conducting research to find the perfect balance of fructose and glucose in high-fructose corn syrup (HFCS), used in a variety of soft drinks. The company successfully developed and obtained patent for a new product, “HFCS 70” that maintains the body equal to fructose glucose liquid sugar used in many soft drinks while having the sharp sweetness of fructose, and is about to release the product.
Since its development 50 years ago, there were only three varieties of HFCS until this year, glucose-fructose liquid sugar, fructose-glucose liquid sugar, and high-fructose liquid sugar, commoditization of which made their differentiation difficult. However, by introducing HFCS 70 into the market, the company expects to overturn the stereotypes in the HFCS industry and create a new wind in the industry.
Japan Corn Starch’s new product, HFCS 70 maintains the body while realizing a high level of sharp sweetness. This allows the product to create a flavor different from fructose glucose liquid sugar, high fructose liquid sugar, or crystalline fructose that are mainstream in the soft drink industry, and help the development of delicious drinks with a new type of sweetness. In addition, because HFCS maintains the body while realizing a high level of sharp sweetness, it can be used in products such as highly refreshing and filling jellies.
Japan Corn Starch has obtained licenses such as the first FSSC22000 and HACCP in the industry and ISO22301, which is the international standard for business continuity management system (BCMS). Furthermore, the company has been making efforts such as radiation dose measurement of each product using high-performance equipment, and quantification of odor using odor identification devices. Thus the company is fully equipped for stable distribution of products.
As a comprehensive producer of starch-related products, Japan Corn Starch will continue its commitment to offer reliable, safe, and high quality products that cater our clients’ every need through its thoroughgoing distribution system.
About the Company
Company name: Japan Corn Starch Co., Ltd.
President: Soichiro
Kurachi
Head office: Akasaka Inter City 3F, 1-11-44 Akasaka, Minato
Ward, Tokyo, 107-0052
Tel: +81-3-5570-7000 (operator)
Fax:
+81-3-5570-7001
Mail: corn@japan-cornstarch.com
URL:
http://www.nihon-cornstarch.com/english
Founded:
1867
View source version on businesswire.com: http://www.businesswire.com/news/home/20170216006427/en/
Contact:
Japan Corn Starch Co., Ltd.
Kazuki Hashimoto, +81-566-42-3129
Public
Relations
corn@japan-cornstarch.com
http://www.nihon-cornstarch.com/english
fax:
+81-3-5570-7001
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom